1. Severe Asthma

2. This program will include a discussion of investigational agents not approved by the FDA for use in the US.

3. Severe Asthma: Overview

4. How Is Severe Asthma Defined? ERS/ATS Guidelines

5. How Is Uncontrolled Asthma Defined? ERS/ATS Guidelines

6. How Is Severe Asthma Defined? GINA Guidelines

7. Evolution of Asthma Classification

8. T2-Mediated Inflammation

9. Non-T2-Mediated Inflammation

10. Asthma Phenotypes

11. Severe Asthma Phenotyping

12. Proposed Asthma Phenotypes

13. Asthma Endotypes

14. Selected Asthma Endotypes

15. Potential Application of Asthma Biomarkers

16. Ideal Biomarker Characteristics

17. Severe Asthma Biomarkers

18. Biologics for Severe Asthma

19. Blocking the IgE Allergic Cascade

20. Omalizumab

21. Anti-IL-5 Therapy in Eosinophilic Asthma

22. Mepolizumab

23. Mepolizumab Phase 3 Study Results

24. Reslizumab

25. Reslizumab Phase 3 Study Results

26. Benralizumab

27. Benralizumab Phase 3 Study Results

28. Anti-IL-4/IL-13 Therapy

29. Inhibiting IL-13 in Severe Asthma

30. Dupilumab Phase 2b Study

31. Dupilumab Phase 3 Study

32. Moving Toward Precision Medicine in Severe Asthma

33. Abbreviations

34. Abbreviations (cont)